3005 Ethinamate Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates. 126-52-3 3284 C9H13NO2 167.094630 White powder. 94-96°C 120°C at 3.00E+00 mm Hg 2500 mg/L (at 25°C) Rapidly absorbed following oral administration. The mechanism of action is not known. However, studies have shown that ethinamate inhibits carbonic anhydrases I and II (J Biol Chem. 1992 Dec 15;267(35):25044-50). This inhibition by ethinamate is not sufficiently strong, however, to implicate carbonic anhydrases I and II in the mechanism of action. Hepatic. Half Life: 2.5 hours No indication of carcinogenicity to humans (not listed by IARC). Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents. They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering. 2009-07-21T20:28:12Z 2026-04-03T12:57:02Z Ethinamate C07832 4884 Ethinamate DB01031 true NC(=O)OC1(CCCCC1)C#C C9H13NO2 InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11) GXRZIMHKGDIBEW-UHFFFAOYSA-N 167.205 167.094628665 Exogenous Solid 1.2 HMDB15165 CHEMBL1576 3169 <p>Junkmann, K. and Pfeiffer, H.; US. Patent 2,816,910; December 17, 1957; assigned to<br /> Schering AG, Germany.</p> CHEM002326 DTXSID7023013 NS00024040 1-ethynylcyclohexyl carbamate